Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantheus HoldingsLNTH -2.49%79 EV-to-EBIT is 16.87 as of Jul. 30, 2026, which is 15% above its 10-year median of 14.70. GuruFocus rates LNTH with a GF Score™ of 79/100 and a GF Value™ of $90.50 (Fairly Valued). The stock has 4 warning signs investors should review. Among 692 Drug Manufacturers companies, Lantheus Holdings ranks worse than 53.32% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lantheus Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $5,063 Mil.
Lantheus Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $393 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings EV-to-EBIT Related Terms
Lantheus Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's EV-to-EBIT falls into.
Lantheus Holdings's current Enterprise Value is $6,638 Mil.
Lantheus Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $393 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a EV-to-EBIT of 16.87 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lantheus Holdings and its competitors. This is 15% above median its historical median of 14.70. According to the industry distribution chart, Lantheus Holdings ranks #369 out of 692 companies in the Drug Manufacturers industry, placing it in the top 53.3%.
Is Lantheus Holdings' EV-to-EBIT too high?
Lantheus Holdings' current EV-to-EBIT of 16.87 is 15% above median its 10-year median of 14.70. The Drug Manufacturers industry median EV-to-EBIT is 15.60. Lantheus Holdings' value of 16.87 is 8.1% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #369 out of 692 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lantheus Holdings has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' EV-to-EBIT compare to HIMS and LQDA?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #369 out of 692 companies for EV-to-EBIT. This places Lantheus Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.60. Lantheus Holdings' value of 16.87 is 8.1% above this benchmark. While the company's 10-year median is 14.70 vs. the industry median of 15.60, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.60, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current EV-to-EBIT of 16.87 is 8.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current EV-to-EBIT is 16.87, which is 15% above median its own 10-year median of 14.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Fairly Valued. The stock's GF Value™ is $90.50, compared to a current price of $100.00 — trading 10.5% above its estimated fair value. The current EV-to-EBIT is 16.87, which is 15% above median its 10-year median of 14.70 and 8.1% above the Drug Manufacturers industry median of 15.60. Lantheus Holdings' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current EV-to-EBIT is 16.87 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $100.00 is trading 10.5% above its estimated GF Value™ of $90.50.
GuruFocus considers Lantheus Holdings to be Fairly Valued.
Key valuation signals for LNTH:
EV-to-EBIT: 16.87 (15% above median its 10-year median of 14.70)
GF Value™: $90.50 vs. price of $100.00 (10.5% above fair value)
Industry Position: 8.1% above the Drug Manufacturers median (#369 of 692)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
79GF Score
Get the complete analysis for LNTH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
